Overview


According to FutureWise analysis, the radioligand therapy (RLT) market in 2026 is US$4.19 billion and is expected to reach US$11.24 billion by 2036, at a CAGR of 10.37%.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Radioligand Therapy (RLT) Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Radioligand Therapy (RLT) Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Novartis AG
  • Bayer AG
  • Curium US LLC
  • Eli Lilly And Company
  • Astrazeneca
  • Progenics Pharmaceuticals INC. (Lantheus)
  • Ariceum Therapeutics
  • Telix Pharmaceuticals
  • ITM Isotope Technologies
  • Convergent Therapeutics, INC.
  • Orano SA
  • Actinium Pharmaceuticals, INC.
  • Perspective Therapeutics, INC.
  • Clarity Pharmaceuticals
  • Radiopharm Theranostics LTD.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Lutetium-177 Vipivotide Tetraxetan (Pluvicto)
  • Lutetium-177 Dotatate (Lutathera)
  • Radium-223 Dichloride (Xofigo)
  • Other Product Types

By Target

  • Prostate-Specific Membrane Antigen
  • Somatostatin Receptor
  • Fibroblast Activation Protein
  • Gastrin-Releasing Peptide Receptor
  • Other Targets

By Indication

  • Prostate Cancer
  • Gastroenteropancreatic Neuroendocrine Tumors
  • Small Cell Lung Cancer
  • Hepatocellular Carcinoma
  • Breast Cancer
  • Other Indications

By End User

  • Tertiary Care Academic and Comprehensive Cancer Centers
  • Specialized Nuclear Medicine Centers
  • Hospitals
  • Specialized Clinics
  • Other End Users

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Radioligand Therapy (RLT) Market By Product, By Target, By Indication, By End User and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction

    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology

    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary

    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Radioligand Therapy (RLT) Market Variables, Trends & Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview

    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Radioligand Therapy (RLT) Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Radioligand Therapy (RLT) Market Analysis Tools

    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Radioligand Therapy (RLT) Market By Product Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Lutetium-177 Vipivotide Tetraxetan (Pluvicto)
        2. Lutetium-177 Dotatate (Lutathera)
        3. Radium-223 Dichloride (Xofigo)
        4. Others

  • 8.  Radioligand Therapy (RLT) Market By Target Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Prostate-Specific Membrane Antigen
        2. Somatostatin Receptor
        3. Fibroblast Activation Protein
        4. Gastrin-Releasing Peptide Receptor
        5. Other Targets

  • 9.  Radioligand Therapy (RLT) Market By Indication Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Prostate Cancer
        2. Gastroenteropancreatic Neuroendocrine Tumors
        3. Small Cell Lung Cancer
        4. Hepatocellular Carcinoma
        5. Breast Cancer
        6. Other Indications

  • 10.  Radioligand Therapy (RLT) Market By End User Historical Analysis and Forecast 2026-2036 (USD Million)

    •   1. Tertiary Care Academic and Comprehensive Cancer Centers
        2. Specialized Nuclear Medicine Centers
        3. Hospitals
        4. Specialized Clinics
        5. Other End Users

  • 11.  North America Radioligand Therapy (RLT) Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2026-2036

  • 12.  Latin America Radioligand Therapy (RLT) Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2026-2036

  • 13.  Europe Radioligand Therapy (RLT) Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2026-2036

  • 14.  Asia Pacific Radioligand Therapy (RLT) Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2026-2036

  • 15.  Middle East and Africa Market Analysis 2019-2025 and Forecast 2026-2036 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2019-2025
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2026-2036

  • 16.  Market Share Analysis and Competitive Landscape

    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 17.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Drug Types Offered and Financial Layouts)

    •     1. Novartis AG
        1.1. Company Overview
        1.2. Drug Type Portfolio
        1.3. SWOT Analysis
        1.4. Financial Overview
        1.5. Strategic Overview
          2. Bayer AG
        2.1. Company Overview
        2.2. Drug Type Portfolio
        2.3. SWOT Analysis
        2.4. Financial Overview
        2.5. Strategic Overview
         3. Curium US LLC
        3.1. Company Overview
        3.2. Drug Type Portfolio
        3.3. SWOT Analysis
        3.4. Financial Overview
        3.5. Strategic Overview
          4. Eli Lilly And Company
        4.1. Company Overview
        4.2. Drug Type Portfolio
        4.3. SWOT Analysis
        4.4. Financial Overview
        4.5. Strategic Overview
          5. Astrazeneca
        5.1. Company Overview
        5.2. Drug Type Portfolio
        5.3. SWOT Analysis
        5.4. Financial Overview
        5.5. Strategic Overview
          6. Progenics Pharmaceuticals INC. (Lantheus)
        6.1. Company Overview
        6.2. Drug Type Portfolio
        6.3. SWOT Analysis
        6.4. Financial Overview
        6.5. Strategic Overview
          7. Ariceum Therapeutics
        7.1. Company Overview
        7.2. Drug Type Portfolio
        7.3. SWOT Analysis
        7.4. Financial Overview
        7.5. Strategic Overview
          8. Telix Pharmaceuticals
        8.1. Company Overview
        8.2. Drug Type Portfolio
        8.3. SWOT Analysis
        8.4. Financial Overview
        8.5. Strategic Overview
          9. ITM Isotope Technologies
        9.1. Company Overview
        9.2. Drug Type Portfolio
        9.3. SWOT Analysis
        9.4. Financial Overview
        9.5. Strategic Overview
         10. Convergent Therapeutics, INC.
        10.1. Company Overview
        10.2. Drug Type Portfolio
        10.3. SWOT Analysis
        10.4. Financial Overview
        10.5. Strategic Overview
         11. Orano SA
        11.1. Company Overview
        11.2. Drug Type Portfolio
        11.3. SWOT Analysis
        11.4. Financial Overview
        11.5. Strategic Overview
         12. Actinium Pharmaceuticals, INC.
        12.1. Company Overview
        12.2. Drug Type Portfolio
        12.3. SWOT Analysis
        12.4. Financial Overview
        12.5. Strategic Overview
         13. Actinium Pharmaceuticals, INC.
        13.1. Company Overview
        13.2. Drug Type Portfolio
        13.3. SWOT Analysis
        13.4. Financial Overview
        13.5. Strategic Overview
         14. Actinium Pharmaceuticals, INC.
        14.1. Company Overview
        14.2. Drug Type Portfolio
        14.3. SWOT Analysis
        14.4. Financial Overview
        14.5. Strategic Overview
         15. Actinium Pharmaceuticals, INC.
        15.1. Company Overview
        15.2. Drug Type Portfolio
        15.3. SWOT Analysis
        15.4. Financial Overview
        15.5. Strategic Overview

  • 18.  Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.  FutureWise SME Key Takeaway Points for Client

    •    


Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 113 519 7222
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11